Florida could ban these chemical additives in foods by 2028 if bill passes
TAMPA, Fla. (WFLA) — Florida could ban chemical additives in foods by 2028 under a new bill that was filed on Monday by a Southwest Florida lawmaker.
Sen. Jonathan Martin (R-Fort Myers), filed SB 560 on Monday ahead of the legislative session, which begins next month.
The bill would prohibit any food establishment from manufacturing, selling, or distributing any foods that contain brominated vegetable oil, potassium bromate, propylparaben, red dye 3, blue dye 1, yellow dye 5, benzidine, butylated hydroxyanisole, or butylated hydroxytoluene.
Chemicals included in the ban have been linked to a possible increase in the risk of cancer.
'Some chemicals cause cancer,' Martin said in a post on X. 'They have no place in our food. Period.'
Those who violate the law could be fined up to $5,000 for a first offense, and $10,000 for second and subsequent violations.
If passed by the legislature and signed into law by Gov. Ron DeSantis, the ban would go into effect on Jan. 1, 2028.
Brominated vegetable oil, or BVO, was commonly used in fruit-flavored drinks to prevent the citrus flavor from 'floating to the top,' according to the Food and Drug Administration. The FDA banned the use of BVO in foods on July 3, 2024. Many products have been reformulated to replace BVO, and it's rarely found in U.S. beverages today, according to the agency.
The FDA also recently banned the use of red dye 3.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Recall alert: Orajel teething swabs pulled from shelves over potential fungal contamination
Orajel teething swabs recalled over fungal concerns—here's what parents should know If you have a stash of teething remedies tucked into your medicine cabinet, it may be time to take a second look. Church & Dwight Co., Inc. has issued a voluntary nationwide recall of several swab-based products—including certain Orajel Baby Teething Swabs—due to possible fungal contamination in the cotton tip component. The recall also includes two types of Zicam nasal swabs. According to the FDA's official alert, these fungi could pose a health risk, especially for children or individuals with weakened immune systems. This isn't a reason to panic—but it is a moment to pause and take action. Related: 1.7 million eggs recalled across 9 states after salmonella outbreak All lot numbers of the following products are affected: Orajel Baby Teething Swabs UPC: 310310400002Use: To soothe teething discomfort in babies and toddlers Zicam Cold Remedy Nasal Swabs UPC: 732216301205Use: Homeopathic swab meant to shorten cold duration Zicam Nasal AllClear Swabs UPC: 732216301656Use: Nasal cleansing swabs (discontinued in 2024) Important: This recall does not include other Orajel or Zicam products, such as gels or RapidMelts. Check your medicine cabinet for any of the products above. Look for the UPC code on the packaging. Stop using recalled products immediately. Visit or call 1‑800‑981‑4710 (Mon–Fri, 9 a.m.–5 p.m. ET) for a full refund. Dispose of the product safely—do not donate or give it away. Related: Check your fridge: Cucumber recall hits 15 states after salmonella outbreak The FDA says the risk is highest for individuals with inflamed nasal tissue or weakened immune systems, as the fungal contamination could lead to serious infections, especially in the bloodstream. But if your baby seems healthy and has shown no unusual symptoms, there's no immediate cause for alarm. Still, if you've recently used a recalled swab call your pediatrician and mention the recall for guidance. Recalls like these are unsettling—but they're also a sign that safety systems are working. If you've used these products, take a breath. Take the next step. You're doing the right thing by staying informed and responsive.
Yahoo
22 minutes ago
- Yahoo
Revolutionizing Diagnostics: Digital Pathology Market Growth Report Reach US$1.73 billion by 2030 at 8.0% CAGR
CHICAGO, June 13, 2025 /PRNewswire/ -- The Global Digital Pathology Market is projected to be valued at USD 1.10 billion in 2024 and reach USD 1.73 billion by 2030, growing at a CAGR of 8% according to a new report by The Research Insights. The key driver of this growth is the mounting need for telepathology to enable pathologists to remotely view slides and interact live over distances. The other factor is integrating artificial intelligence (AI) in digital pathology systems, boosting diagnostics through automated image analysis and predictive analytics. The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the Digital Pathology Market growth of 8.0% comprises a vast array of Product, Type, Application, End-Use, and Geography which are expected to register strength during the coming years. For More Information and To Stay Updated on The Latest Developments in The Global Digital Pathology Market, Download FREE Sample Pages: Market Overview and Growth Trajectory: Digital Pathology Market Growth: According to an exhaustive report by The Research Insights, the Digital Pathology Market is experiencing significant growth. The worldwide digital pathology market expansion results from multiple technological advancements alongside clinical and systemic changes that mirror a comprehensive shift in diagnostic methods and healthcare service delivery. The rapid integration of artificial intelligence (AI) and machine learning algorithms serves as a key driving force in pathology because they improve diagnostic accuracy while enhancing workflow efficiency and decision-making support. Precision medicine's rising requirement along with individually tailored treatment plans drives the need for digital platforms that integrate histopathological data with genomic and clinical information. The worldwide scarcity of pathologists in developing markets forces healthcare infrastructures to implement digital pathology systems that consolidate diagnostic capabilities and allow for remote consultations through telepathology. The global rise in cancer cases demands the development of diagnostic solutions that operate more quickly and can scale to meet increasing needs. The FDA's regulatory approvals and standardization efforts are helping to validate digital pathology systems which leads to their broader use. The focus on digital health infrastructure and remote healthcare solutions after COVID-19 has solidified digital pathology's essential role in modern diagnostic processes. Rising Prevalence of Chronic Diseases and Cancer:The increasing global prevalence of chronic illnesses such as cancer alongside cardiovascular and autoimmune diseases creates demand for digital pathology through the need for accurate diagnostic results. Cancer stands as a primary focus area because the World Health Organization (WHO) reports that it causes almost 10 million deaths each year. The growing number of cancer cases increases the need for precise histopathological assessments which play a critical role in cancer staging and treatment planning as well as determining patient glass-slide microscopy requires extensive time commitment while demanding substantial labor effort and remains susceptible to mistakes by human operators. Digital pathology allows for complete slide digitization which supports storage capabilities as well as analysis and sharing functions. Digital platforms play an essential role in oncology and chronic disease management through improved diagnostic accuracy and simpler access to second opinions and telepathology. The requirement for high-throughput pathology services becomes even stronger when centralized laboratories need to serve extensive populations. For Detailed Market Insights, Visit: Innovations in Whole Slide Imaging (WSI) technology combined with artificial intelligence (AI) integration are driving major changes in digital pathology:Progress in imaging technology alongside improvements in data storage and artificial intelligence (AI) development is revolutionizing digital pathology. The development of Whole Slide Imaging (WSI) now enables the capture of ultra-high-resolution images which can be stored and distributed with very little delay. After digitization these images become suitable for AI analysis which helps detect patterns and anomalies while classifying tissue types with greater consistency than manual workflows now frequently utilize AI-powered tools to help pathologists identify diseases at early stages while simultaneously quantifying biomarkers and standardizing interpretations. The algorithms designed for breast and prostate cancer detection improve diagnostic efficiency and minimize inter-observer variability by highlighting suspicious regions and providing grading suggestions. Real-time slide sharing capabilities of cloud-based platforms allow institutions to collaborate on diagnostics without being limited by geographic distances. This technological progress improves diagnostic speed and accuracy while shortening turnaround time which is essential for treating life-threatening conditions. Growing Adoption of Telepathology and Remote Consultations:The pandemic hastened digital health technology implementation with digital pathology becoming another beneficiary of this trend. Telepathology has become an essential diagnostic tool due to increasing demands for remote consultations and second opinions. Digital platforms now enable hospitals and laboratories to share slides across regions and countries with specialists which allows for expert reviews and collaborations to occur promptly without needing to transport specimens is emerging as a critical solution to the worldwide inequality in pathology services. Rural regions and areas with limited resources experience a significant lack of trained pathologists. Through digital pathology centralized specialists review cases from distant locations which closes existing healthcare gaps to advance healthcare equity. Digital pathology platforms provide educational institutions with benefits for training and research because students and researchers can access actual slides from any location at any time. Stay Updated on The Latest Digital Pathology Market Trends: Geographical Insights: The North American market achieved a 40.7% share of the global market in 2023 because government-backed initiatives advanced pathology technology. The dominance resulted from continuous R&D funding and the growing implementation of digital imaging technologies. Their influence grew stronger in the region because prominent players focused on creating innovative solutions to meet the needs of the local population. Market expansion is propelled by academic research and disease diagnosis needs for digital pathology because institutions aim to use its capabilities to enhance diagnostic accuracy and treatment results. Between 2024 and 2030 the Asia Pacific region will achieve the highest Compound Annual Growth Rate (CAGR) thanks to increased digitalization activities combined with medical research investments and the growing use of digital imaging technologies in developing economies. The rising occurrence of cancer cases continues to drive market growth which highlights the necessity for new treatment options that will advance market expansion. Global Digital Pathology Market Segmentation and Geographical Insights: Based on Product, the digital pathology market is divided into, Software, Device, and Storage System. The device segment dominated the market share in 2023 with 51.72% and is expected to experience substantial growth over the projected period. Based on Type, the digital pathology market is divided into, Human Pathology, and Veterinary Pathology. The human aspect of digital pathology is playing a pivotal role, accounting for approximately 60.0% market share in 2023. Based on Application, the digital pathology market is divided into, Drug Discovery & Development, Academic Research, and Disease Diagnosis. The academic research segment led the market share in 2023, accounting for 45.7%, and is expected to continue its dominance from 2024 to 2030 due to ongoing research in cancer therapy development and high adoption rates of digital pathology in various studies. Based on End Use, the digital pathology market is divided into, Hospitals, Biotech & Pharma Companies, Diagnostic Labs, and Academic & Research Institutes. The healthcare sector led the market share in 2023 with a notable presence of 36.7%. The Digital Pathology Market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Purchase Premium Copy of Global Digital Pathology Market Size and Growth Report (2024-2030) at: Key Players and Competitive Landscape: The Global Digital Pathology Market is characterized by the presence of several major players, including: Leica Biosystems Nussloch GmbH (Danaher) Hamamatsu Photonics, Inc. Koninklijke Philips N.V. Olympus Corporation F. Hoffmann-La Roche Ltd. Mikroscan Technologies, Inc. Inspirata, Inc. Epredia (3DHISTECH Ltd.) Visiopharm A/S Huron Technologies International Inc. ContextVision AB CellaVision HANGZHOU ZHIWEI INFORMATION TECHNOLOGY CO. LTD. (MORPHOGO) West Medica Produktions- und Handels- GmbH (West Medica) aetherAI IBEX (IBEX MEDICAL ANALYTICS) SigTuple Technologies Private Limited Morphle Labs, Inc Bionovation Biotech, Inc. These companies are adopting strategies such as new product launches, joint ventures, and geographical expansion to maintain their competitive edge in the market. Global Digital Pathology Market Recent Developments and Innovations: In March 2024: Koninklijke Philips N.V. (Netherlands) formed an expanded partnership with AWS to create secure, scalable cloud-based digital pathology solutions. The collaboration between AWS and Philips will improve workflow efficiency while ensuring smooth integration with current healthcare systems to provide complete patient care. In February 2024: Roche entered into a partnership with Path AI to build an AI-powered digital pathology algorithm for companion diagnostics. Through this partnership Roche will speed up its capacity to fulfill biopharma companies' needs who seek to create AI-driven companion diagnostics and deliver complete solutions. In March 2023: Agilent Technologies partnered with Hamamatsu Photonics K.K. Agilent Technologies teamed up with Hamamatsu Photonics K.K. to integrate the NanoZoomer range with the S360MD Slide scanner system into their comprehensive digital pathology solution. In March 2022: Roche Diagnostics partnered with SRL Diagnostics. In collaboration with Roche Diagnostics, SRL Diagnostics intended to upgrade its Fortis Memorial Research Institute laboratory facilities. For Region-Specific Market Data, Check Out Brief Sample Pages: Frequently Asked Questions (FAQs): What is the forecasted market size of the Digital Pathology Market in 2030? The forecasted market size of the Digital Pathology Market is USD 1.73 billion in 2030. Who are the leading players in the Digital Pathology Market? The key players in the Digital Pathology Market include, Leica Biosystems Nussloch GmbH (Danaher); Hamamatsu Photonics, Inc.; Koninklijke Philips N.V.; Olympus Corp.; F. Hoffmann-La Roche Ltd.; Mikroscan Technologies, Inc.; Inspirata, Inc.; Epredia (3DHISTECH Ltd.); Visiopharm A/S; Huron Technologies International Inc.; ContextVision AB; HANGZHOU ZHIWEI INFORMATION TECHNOLOGY CO. LTD. (MORPHOGO); West Medica Produktions- und Handels- GmbH (West Medica); aetherAI; IBEX (IBEX MEDICAL ANALYTICS); SigTuple Technologies Private Limited; Morphle Labs, Inc; and Bionovation Biotech, Inc. What are the major drivers for the Digital Pathology Market? Several key factors are driving this expansion, including the growing adoption of AI-enabled digital pathology. Which is the largest region during the forecasted period in the Digital Pathology Market? The North American market achieved a 40.7% share of the global market in 2023 because government-backed initiatives advanced pathology technology. Which is the largest segment, by product, during the forecasted period in the Digital Pathology Market? The device segment dominated the market share in 2023 with 51.72% and is expected to experience substantial growth over the projected period. Conclusion: Digital imaging advancements and AI along with data analytics improvements lead to major transformations within the global digital pathology market which meets healthcare systems' needs for swifter and more precise diagnostic procedures. The spread of chronic diseases combined with telepathology demand growth and pathologist workforce deficits has sped up the implementation of digital pathology technologies. Modern systems provide the ability for immediate remote medical consultations alongside more efficient data exchange and better-informed decisions through artificial intelligence that analyses medical images. The combination of EHR integration with advanced interoperability and cloud storage solutions leads to better diagnostic precision and operational efficiency. Digital pathology stands as a fundamental component of precision medicine and laboratory automation while global healthcare digitization progresses alongside evolving regulatory frameworks and advanced data security technologies. The market's growth momentum continues as it connects with wider digital health movements and shifts towards value-based care approaches. Need A Diverse Region or Sector? Customize Research to Suit Your Requirement: The report from The Research Insights, therefore, provides several stakeholders—healthcare providers, diagnostic laboratories, research institutions, pharmaceutical companies, and regulatory agencies—with valuable insights into how to successfully navigate this evolving market landscape and unlock new opportunities. With projected growth to US$ 1.73 billion by 2030, the Global Digital Pathology Market represents a significant opportunity for AI technology developers, cloud service providers, medical imaging software companies, digital health startups, and telepathology platform vendors. Check out more related studies published by The Research Insights: U.S. And Europe Digital Pathology Market - The US and European digital pathology market is poised for significant growth, driven by increasing efforts to harness this technology for enhanced disease diagnosis and improved pathology practices. Currently valued at USD 578.6 million in 2022, the market is projected to expand at a compound annual growth rate (CAGR) of 7.2% from 2023 to 2030. In the US, the FDA has classified digital pathology as Class II devices suitable for primary diagnosis, paving the way for wider adoption. Pathology Laboratories Market: The Global Pathology Laboratories Market is expected to reach at USD 612.22 billion by 2030, according to a new report by The Research Insights. It is projected to expand at a CAGR of 8.1% during the forecast period. This growth is driven by the expanding healthcare infrastructure in developing countries, as well as an increasing demand for regular medical check-ups and enhanced reimbursement policies for diagnostic tests. AI in Pathology Market - The AI in Pathology Market size is set to grow from USD 92.32 million in 2025 to USD 434.16 million by 2034, at a CAGR of 19.07%. The AI for Pathology Market describes how artificial intelligence technologies including machine learning algorithms and neural networks process pathology data to aid clinical decision-making while boosting diagnostic precision and workflow productivity. The medical field of pathology which focuses on disease study and diagnosis through tissue, organ, and fluid examination is experiencing a digital shift through AI integration. Anatomic Pathology Market - The global anatomic pathology market continues to expand its reach, with valued sales reaching USD 30.16 billion in 2022. As we look ahead, the market is projected to experience a significant compound annual growth rate (CAGR) of 8.7% from 2023 to 2030. This surge in growth can be attributed to the increasing adoption of biomarkers in clinical settings, which has revolutionized the way pathologists analyze molecular-level mechanisms. Precision Pathology for Cancer Market: The Research Insights report reveals that Precision pathology for cancer applies advanced technological methods to produce customized diagnostic and therapeutic approaches based on individual tumor biology. This innovative method combines histological, genomic and bioinformatic knowledge to enable healthcare providers to develop individualized treatment plans which lead to improved patient results. Browse More related reports on Healthcare Industry Market Reports – About Us: The Research Insights provides thoroughly conducted research which is backed up by real-time statistics and data. Our experts are eager to help you with any information required under the sun. The key to our success is keeping abreast with the markets, industries, and ever-changing consumer trends that matter. Our market research professionals have in-depth knowledge and expertise across various domains that includes IT and Telecom, Emerging Technologies, Consumer Offerings, Manufacturing and Others. We are committed to reviewing the scope and procedure of the research studies that you select and provide you with an accurate guidance in order to assist you in taking the correct business decisions. Contact Us:If you have any queries about this report or if you would like further information, please contact us: Contact Person: Kaushik RoyE-mail: sales@ +1-312-313-8080Blog: Release: News: | Logo: View original content: SOURCE The Research Insights


Time Business News
26 minutes ago
- Time Business News
Beyond the Little Blue Pill: Exploring Generic Sildenafil for ED
1. Understanding Erectile Dysfunction 2. The Rise of Sildenafil 3. Differences Between Brand Name and Generic Sildenafil 4. How Generic Sildenafil Works 5. Benefits of Choosing Generic Sildenafil 6. Potential Side Effects and Precautions 7. Who Can Use Generic Sildenafil? 8. Availability and Accessibility 9. Comparing Costs: Brand Name vs. Generic 10. Real-Life Success Stories 11. Future Innovations in ED Treatment — Erectile dysfunction (ED) is a common condition that affects millions of men worldwide, leading to significant emotional and psychological distress. It is characterized by the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. While occasional difficulties are normal, persistent issues warrant attention. ED can stem from various causes, which can be broadly categorized into physical and psychological factors: – Physical Causes: These include cardiovascular disease, diabetes, hormonal imbalances, obesity, and certain medications. – Psychological Causes: Stress, anxiety, depression, and relationship issues can contribute to ED. Understanding these causes is crucial as they inform the treatment approach, which may include lifestyle changes, therapy, or medication. — The introduction of sildenafil in the late 1990s revolutionized the treatment landscape for ED. Marketed initially under the well-known brand name Viagra, sildenafil quickly became synonymous with ED treatment. Before sildenafil's approval by the FDA in 1998, options for treating ED were limited and often invasive, such as penile injections or implants. Sildenafil offered a non-invasive alternative that was both effective and easy to use, leading to widespread adoption. — While Viagra remains a popular choice, many patients are now turning to generic sildenafil due to its affordability and accessibility. Generic sildenafil contains the same active ingredient as Viagra—sildenafil citrate—and works in the same way. It is subject to stringent regulations to ensure it matches the efficacy and safety profile of its branded counterpart. – Cost: Generic versions are typically less expensive due to reduced marketing and development costs. – Brand Variability: Multiple pharmaceutical companies produce generic sildenafil, which may lead to variations in inactive ingredients. — Understanding the mechanism of action is essential for appreciating how generic sildenafil alleviates symptoms of ED. Sildenafil belongs to a class of drugs known as phosphodiesterase type 5 (PDE5) inhibitors. It works by enhancing blood flow to the penis by relaxing blood vessels—a process triggered during sexual stimulation. – Onset: Typically begins working within 30 to 60 minutes. – Duration: Effects can last up to four hours, providing ample time for sexual activity. — Opting for generic sildenafil offers several advantages beyond cost savings. – Affordability: Significantly cheaper than branded alternatives. – Wide Availability: Accessible at most pharmacies with a prescription. – Proven Efficacy: Clinical trials confirm its effectiveness in treating ED across various populations. Choosing generic sildenafil allows patients to manage their condition without financial strain, making it an attractive option for many men worldwide. — As with any medication, it's essential to be aware of potential side effects when using generic sildenafil. – Headaches – Flushing – Indigestion – Nasal congestion Though rare, severe side effects such as vision or hearing loss require immediate medical attention. Patients should disclose their full medical history to their healthcare provider to avoid contraindications with other medications or conditions such as heart disease or high blood pressure. — Generic sildenafil is suitable for most men experiencing ED; however, some individuals may require additional considerations. Men over the age of 18 who experience difficulty achieving or maintaining an erection may consider this treatment option after consulting with a healthcare provider. Special caution is advised for those with underlying health conditions or those taking medications that could interact negatively with sildenafil. — The availability of generic sildenafil has expanded significantly since its introduction into the market. In most countries, including the UK where sites like Post My Meds operate, a prescription is required to purchase sildenafil legally. This ensures proper medical oversight and reduces the risk of misuse. Online pharmacies have made accessing this medication more convenient than ever while ensuring privacy and discretion for users seeking treatment. — One of the most compelling reasons patients opt for generic sildenafil is its cost-effectiveness compared to brand-name versions. – Brand Name (Viagra): Generally priced higher due to brand recognition and initial research investments. – Generic Versions: Provide substantial savings without compromising on quality or efficacy. This price difference enables broader access among diverse socioeconomic groups who need effective ED treatment but may have budget constraints. — Real-life testimonials provide valuable insights into how generic sildenafil impacts users' lives positively beyond clinical statistics alone. Consider John, a 55-year-old office worker who struggled with ED due to stress-related factors: – Pre-treatment: Experienced anxiety affecting relationships. – Post-treatment with Generic Sildenafil: Regained confidence; improved personal relationships; reported satisfaction with both effectiveness & affordability aspects. Such stories underscore both practical benefits & emotional relief offered by generics like these. — The field continues evolving beyond traditional methods like oral medications towards holistic approaches integrating lifestyle interventions alongside pharmaceutical advancements such as: – Gene Therapy: Ongoing studies explore potential gene editing techniques targeting root causes directly within affected tissues. – Regenerative Medicine: Utilization stem cells show promise restoring function naturally over time rather than merely symptom management alone. These innovations hold exciting potential reshaping future therapeutic landscapes offering hope those seeking comprehensive solutions tailored individual needs. In conclusion, exploring beyond little blue pills reveals promising opportunities improve quality life countless individuals globally facing challenges associated erectile dysfunction today tomorrow alike. TIME BUSINESS NEWS